MTOR and prostate cancer: MOA:Ang ranks 2nd among the MOA’s listed for group A and is associated with defective RPTOR, SOX9 and MTOR. Oncogenic activation of the phosphatidylinositol-3-kinase (PI3K), and mammalian target of rapamycin (MTOR) facilitates tumor formation, disease progression, therapeutic resistance, and the sensitivity of prostate cancer cell lines to PI3K-AKT-mTOR-targeted therapies [46].